Palmitoyl ethanolamide-d4 (PEA-d4) contains four deuterium atoms at the 1,1′, 2, and 2′ positions. It is intended for use as an internal standard for the quantification of PEA by GC- or LC-mass spectrometry. Palmitoyl ethanolamide (PEA) is an endogenous cannabinoid found in brain, liver, and other mammalian tissues.{2415} PEA has also been isolated from egg yolk, and found to have anti-anaphylactic and anti-inflammatory activity in vitro.{1633} PEA is an endocannabinoid which has been shown to significantly elevate cAMP in cells expressing CB2 receptors. However, its affinity for CB2 receptors is relatively low, at about 10 µM. CB1 receptors have no appreciable affinity for PEA.{1134}
Available on backorder
An internal standard for the quantification of PEA
Formal name: N-(2-hydroxyethyl-1,1′,2,2′-d4)-hexadecanamide
Synonyms: Palmidrol-d4|PEA-hydroxyethyl-1,1,2,2-d4
Molecular weight: 303.5
CAS: 946524-34-1
Purity: ≥99% deuterated forms (d1-d4)
Formulation: A solution in ethanol
1,2-Dipalmitoyl-sn-glycero-3-PC (DPPC) is a zwitterionic glycerophospholipid commonly used in the formation of lipid monolayers, bilayers, and liposomes for use in a variety of applications.{14480,24261,14478,14479} It has been used in the formation of proteoliposomes for implantation of γ-glutamyl transpeptidase into human erythrocyte membranes.{14478} Incorporation of glycosphingolipid antigens into DPPC-containing liposomes increases the immunogenicity of the antigens in mice.{14479}
Available on backorder
Cyclin-dependent kinases (CDKs) are key regulators of cell cycle progression and are therefore promising targets for cancer therapy. (R)-Roscovitine is a potent inhibitor of Cdk2/cyclin E with an IC50 value of 0.1 µM.{14988} It also inhibits Cdk7/cyclin H, Cdk5/p35, and cell division cycle (cdc)/cyclin B with IC50 values of 0.49, 0.16, and 0.65 µM, respectively.{14987,14988,14991} (R)-Roscovitine inhibits the growth of rapidly proliferating cells with an average IC50 value of 15.2 µM against a panel of 19 human tumor cell lines.{14988} In murine models of polycystic kidney disease, (R)-roscovitine effectively inhibited disease progression at doses of 50-100 mg/kg.{14564}
Available on backorder
Cyclin-dependent kinases (CDKs) are key regulators of cell cycle progression and are therefore promising targets for cancer therapy. (R)-Roscovitine is a potent inhibitor of Cdk2/cyclin E with an IC50 value of 0.1 µM.{14988} It also inhibits Cdk7/cyclin H, Cdk5/p35, and cell division cycle (cdc)/cyclin B with IC50 values of 0.49, 0.16, and 0.65 µM, respectively.{14987,14988,14991} (R)-Roscovitine inhibits the growth of rapidly proliferating cells with an average IC50 value of 15.2 µM against a panel of 19 human tumor cell lines.{14988} In murine models of polycystic kidney disease, (R)-roscovitine effectively inhibited disease progression at doses of 50-100 mg/kg.{14564}
Available on backorder
1,2-Dipalmitoyl-sn-glycero-3-PC (DPPC) is a zwitterionic glycerophospholipid commonly used in the formation of lipid monolayers, bilayers, and liposomes for use in a variety of applications.{14480,24261,14478,14479} It has been used in the formation of proteoliposomes for implantation of γ-glutamyl transpeptidase into human erythrocyte membranes.{14478} Incorporation of glycosphingolipid antigens into DPPC-containing liposomes increases the immunogenicity of the antigens in mice.{14479}
Available on backorder